Literature DB >> 1712717

Low dose loop diuretics in essential hypertension. Experience with torasemide.

I Achhammer1, P Metz.   

Abstract

Diuretics belong to the class of antihypertensive drugs recommended for first-line therapy of essential hypertension. Although they are widely and effectively used for the treatment of hypertension, the question remains whether their possible negative influence on metabolic and electrolyte parameters could partly offset the benefit of blood pressure reduction with respect to reduction of coronary artery disease. Recently published data demonstrate that much lower doses of thiazides exert the same antihypertensive effect as the higher doses used in the past and even prescribed today. These lower doses produce relatively little change in biochemical parameters. Thus, the postulated risks can be avoided by using the lowest effective dose. Traditionally, loop diuretics of the furosemide (frusemide) type are rarely used as first-line antihypertensive agents. They seem to display less efficacy coupled with an intense diuresis when used in standard available doses. However, there is evidence that newly developed loop diuretics, in lower doses than used in congestive heart failure, are effective antihypertensive agents. For example, torasemide 2.5mg once daily, which does not exert a significant diuresis over 24 hours compared with placebo, lowers elevated blood pressure to a similar extent than thiazides or related compounds. This antihypertensive effect is accompanied by less, if any, changes in metabolic or electrolyte parameters compared with widely used standard diuretics such as hydrochlorothiazide, indapamide or chlorthalidone. The influence on serum potassium and magnesium is similar to or even less than fixed combinations of hydrochlorothiazide and triamterene or amiloride. Thus, low-dose torasemide constitutes an alternative to established thiazide antihypertensive therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1712717     DOI: 10.2165/00003495-199100413-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  34 in total

1.  Regression of left ventricular hypertrophy in hypertension: comparative effects of three different drugs.

Authors:  P J Mace; W A Littler; D R Glover; D B Rowlands; T J Stallard
Journal:  J Cardiovasc Pharmacol       Date:  1985       Impact factor: 3.105

2.  Dose response to chlorthalidone in patients with mild hypertension. Efficacy of a lower dose.

Authors:  B J Materson; J R Oster; U F Michael; S M Bolton; Z C Burton; J E Stambaugh; J Morledge
Journal:  Clin Pharmacol Ther       Date:  1978-08       Impact factor: 6.875

3.  Antihypertensive efficacy of low dose torasemide in essential hypertension: a placebo-controlled study.

Authors:  A G Dupont; D Schoors; R O Six; L Vanhaelst
Journal:  J Hum Hypertens       Date:  1988-12       Impact factor: 3.012

Review 4.  An assault on old friends: thiazide diuretics under siege.

Authors:  W G Thompson
Journal:  Am J Med Sci       Date:  1990-09       Impact factor: 2.378

5.  The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide.

Authors:  G McVeigh; D Galloway; D Johnston
Journal:  BMJ       Date:  1988-07-09

6.  Effects of indapamide on left ventricular mass and function in systemic hypertension with left ventricular hypertrophy.

Authors:  M Komajda; K Klimczak; B Boutin; F Brackman; D Guez; Y Grosgogeat
Journal:  Am J Cardiol       Date:  1990-05-02       Impact factor: 2.778

7.  MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-13

8.  Study of the tolerance and diuretic properties of torasemide following oral or intravenous administration to healthy volunteers.

Authors:  R Lambe; O Kennedy; M Kenny; A Darragh
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  Clinical evaluation of muzolimine and indapamide during treatment for essential hypertension.

Authors:  R Kirsten; K H Molz; I Tzonev; K Nelson
Journal:  Z Kardiol       Date:  1985

10.  The Captopril Prevention Project: a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. The CAPPP Group.

Authors: 
Journal:  J Hypertens       Date:  1990-11       Impact factor: 4.844

View more
  8 in total

Review 1.  Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention.

Authors:  Samuel J Mann; Michael E Ernst
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

Review 2.  Clinicopharmacological reappraisal of the potency of diuretics.

Authors:  A J Reyes; W P Leary
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

Review 3.  Renal excretory responses to single and repeated administration of diuretics in healthy subjects: clinical connotations.

Authors:  A J Reyes; W P Leary
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

Review 4.  Clinical pharmacokinetics and pharmacodynamics of torasemide.

Authors:  H Knauf; E Mutschler
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 5.  Torasemide. An update of its pharmacological properties and therapeutic efficacy.

Authors:  C J Dunn; A Fitton; R N Brogden
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

Review 6.  Loop Diuretics in the Treatment of Hypertension.

Authors:  Line Malha; Samuel J Mann
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

Review 7.  Benefits and risks of torasemide in congestive heart failure and essential hypertension.

Authors:  D C Brater
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

Review 8.  Torasemide in comparison with thiazides in the treatment of hypertension.

Authors:  P Baumgart
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.